A James Mixson
Overview
Explore the profile of A James Mixson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leng Q, Anand A, Mixson A
Molecules
. 2024 Dec;
29(23.
PMID: 39683699
Over 20 years have passed since siRNA was brought to the public's attention. Silencing genes with siRNA has been used for various purposes, from creating pest-resistant plants to treating human...
2.
Leng Q, Anand A, Mixson A
Biochem Biophys Res Commun
. 2024 Aug;
738:150566.
PMID: 39180892
Cationic polymers that bind with the plasmids to form polyplexes protect the DNA from enzymatic degradation and improve cellular and tissue uptake. Complete or near complete gel retardation of the...
3.
Leng Q, He J, Anand A, Mixson A
Methods Mol Biol
. 2024 Jun;
2822:367-386.
PMID: 38907929
Transfection with mRNA has been considered superior to that with plasmids since the mRNA can be translated to a protein in the cytosol without entering the nucleus. One disadvantage of...
4.
Agrawal A, Leng Q, Imtiyaz Z, Mixson A
Biochem Biophys Res Commun
. 2023 Aug;
678:33-38.
PMID: 37619309
Histidine-containing polymers show promise in their transport of nucleic acids in vitro and in vivo. In addition to the pH-buffering histidine component, the polymer often contains a protonated component at...
5.
Leng Q, Imtiyaz Z, Woodle M, Mixson A
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242725
With less than one percent of systemically injected nanoparticles accumulating in tumors, several novel approaches have been spurred to direct and release the therapy in or near tumors. One such...
6.
Imtiyaz Z, He J, Leng Q, Agrawal A, Mixson A
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36365245
Accumulating chemotherapeutic drugs such as doxorubicin within a tumor while limiting the drug dose to normal tissues is a central goal of drug delivery with nanoparticles. Liposomal products such as...
7.
Leng Q, Mixson A
Discov Med
. 2022 Mar;
33(168):7-12.
PMID: 35292130
Over six million people have died worldwide as a result of SARS-CoV-19 (Covid-19). Several major and minor variant waves of Covid-19 including the Alpha (B.1.1.7), Delta (B.1.617.2), and the Omicron...
8.
Xu S, He J, Imtiyaz Z, Agrawal A, Woodle M, Mixson A
J Gene Med
. 2021 Oct;
24(1):e3396.
PMID: 34713552
Background: We previously determined that polyplexes formed by linear H2K peptides were more effective in transfecting tumors in vivo than polyplexes formed by branched H2K4b-20 peptides. Based on trypsin digest...
9.
He J, Xu S, Leng Q, Mixson A
J Gene Med
. 2020 Nov;
23(2):e3295.
PMID: 33171540
Background: Previously, we determined that four-branched histidine-lysine (HK) peptides were effective carriers of plasmids and small interfering RNA. In the present study, we compared several branched HK carriers and, in...
10.
He J, Xu S, Mixson A
Pharmaceutics
. 2020 Aug;
12(8).
PMID: 32823960
Histidines incorporated into carriers of nucleic acids may enhance the extracellular stability of the nanoparticle, yet aid in the intracellular disruption of the nanoparticle, enabling the release of the nucleic...